Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.68 |
| ▸ | CCR3 | P51677 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CASR | P41180 | 3/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26804104 | 0.84 | SLC6A3 (0.74) | SLC6A3MEN1KMT2AMAPTHTT | |
| SCHEMBL21675567 | 0.82 | TP53 (0.57) | CCR3MEN1KMT2AMAPTHTT | |
| SCHEMBL26804110 | 0.81 | SLC6A3 (0.78) | SLC6A3KMT2ACASR | |
| SCHEMBL23902831 | 0.81 | SLC6A3 (1.00) | SLC6A3CASR | |
| SCHEMBL7814055 | 0.79 | MEN1 (0.60) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL26804140 | 0.78 | SLC6A3 (0.72) | SLC6A3HTTCASRSMN1; SMN2ALDH1A1 | |
| SCHEMBL5759619 | 0.78 | MEN1 (0.61) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL26804098 | 0.77 | SLC6A3 (0.85) | SLC6A3KMT2ACASR | |
| SCHEMBL21682973 | 0.77 | SLC6A3 (1.00) | SLC6A3KMT2AMAPTRAB9ACASR | |
| SCHEMBL26804101 | 0.77 | SLC6A3 (0.78) | SLC6A3KMT2ACASRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2023-11-30 | — | — | US | disclosed |
| US-20210309607-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TEXAS TECH UNIVERSITY SYSTEM (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309607-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TP53, ULK1, TFEB | SLC6A3 1928/4885CCR3 4420/4885MEN1 4167/4885 |
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TFEB, TP53, BECN1 | SLC6A3 2908/4885CCR3 3646/4885MEN1 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.